Integene International Overview

  • Founded
  • 2010
Founded
  • Status
  • Private
  • Latest Deal Type
  • Accelerator/​Inc
  • Latest Deal Amount
  • $300K
Latest Deal Amount
  • Investors
  • 2

Integene International General Information

Description

Developer of a platform technology intended to treat vascular diseases. The company's technology is developed for the treatment of cardiovascular ischemic disease using combinations of gene and stem cell procedures, enabling patients suffering from vascular diseases gets the required treatment.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Accelerator/Incubator Backed
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Primary Office
  • 1951 North West 7th Avenue
  • Suite 300
  • Miami, FL 33136
  • United States
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Integene International Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Accelerator/Incubator 13-Aug-2014 $300K 00000 Completed Generating Revenue
2. Angel (individual) Completed Startup
1. Grant $10M Completed Startup
To view Integene International’s complete valuation and funding history, request access »

Integene International Executive Team (3)

Name Title Board Seat Contact Info
Keith Webster Ph.D President & Founder
You’re viewing 1 of 3 executive team members. Get the full list »

Integene International Board Members (2)

Name Representing Role Since
Eduardo De Marchenna MD Integene International Board Member 000 0000
You’re viewing 1 of 2 board members. Get the full list »

Integene International Investors (2)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Florida Institute for the Commercialization of Public Research Not-For-Profit Venture Capital Minority 000 0000 000000 0
National Institutes of Health Government 000 0000 000000 0
To view Integene International’s complete investors history, request access »